ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 122,48
0,86%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Jounce Therapeutics Inc (JNCE)

  7. Jounce Therapeutics Inc (JNCE) Actualités

JNCE

Jounce Therapeutics (JNCE)

Jounce Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:JNCE
DateHeureSourceTitreSymboleSociété
14/02/202414h50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JNCEJounce Therapeutics Inc
15/05/202313h41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202322h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202322h35Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202312h09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202314h40Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313h31Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313h25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313h23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313h08Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202302h35GlobeNewswire Inc.Jounce Therapeutics Announces Closing of Tender OfferNASDAQ:JNCEJounce Therapeutics Inc
28/04/202320h48Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202313h55Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202308h00GlobeNewswire Inc.Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcNASDAQ:JNCEJounce Therapeutics Inc
27/03/202320h12Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:JNCEJounce Therapeutics Inc
27/03/202315h00GlobeNewswire Inc.Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsNASDAQ:JNCEJounce Therapeutics Inc
16/03/202321h30GlobeNewswire Inc.Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerNASDAQ:JNCEJounce Therapeutics Inc
15/03/202302h00GlobeNewswire Inc.Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:JNCEJounce Therapeutics Inc
14/03/202322h01Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:JNCEJounce Therapeutics Inc
10/03/202315h24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:JNCEJounce Therapeutics Inc
06/03/202322h00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202322h56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202308h30GlobeNewswire Inc.Redx and Jounce Announce Recommended Business CombinationNASDAQ:JNCEJounce Therapeutics Inc
22/02/202323h00GlobeNewswire Inc.Jounce Therapeutics Announces RestructuringNASDAQ:JNCEJounce Therapeutics Inc
14/02/202322h55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:JNCEJounce Therapeutics Inc
09/01/202312h02Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:JNCEJounce Therapeutics Inc
27/12/202223h24Dow Jones NewsGilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202222h30Business WireGilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202222h30GlobeNewswire Inc.Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
08/12/202213h50GlobeNewswire Inc.Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressNASDAQ:JNCEJounce Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JNCE

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
NYSE
DIS
Walt Disney
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
EU
CAP
Capgemini
EU
ML
Michelin
EU
ORA
Orange
EU
PX4
SBF 120
EU
HO
Thales
EU
BN
Danone
EU
ACA
Credit Agricole
EU
AF
Air FranceKLM
NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés